Wave Life Sciences reports 46% mHTT lowering in HD trial; allele-selective silencing demonstrated

Wave Life Sciences Ltd.

SELECT-HD: 30 mg WVE-003 Q8W showed 46% mean mHTT reduction vs placebo at 24 weeks (p=0.0007); 44% at 28 weeks (p=0.0002).
Wild-type HTT preserved; allele-selective silencing confirmed.
mHTT reduction correlated with slowing of caudate atrophy (R=-0.50, p=0.047), an imaging biomarker predictive of clinical outcomes.
Generally safe and well-tolerated; no serious adverse events reported.
Cash runway into Q4 2025; Wave to discuss accelerated approval path with regulators.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.